Advanced search
Publication Cover
OncoTargets and Therapy Volume 16, 2023 - Issue
Submit an article Journal homepage
166
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

Partial Response to Crizotinib in a Lung Adenocarcinoma Patient with a Novel FBXO11 (Intergenic)-ALK (Exon 20-29) Fusion

Jing He1 Medical Oncology Department, Jiangsu Province Hospital, Nanjing, Jiangsu, 210029, People’s Republic of China
,
Youyuan Yao1 Medical Oncology Department, Jiangsu Province Hospital, Nanjing, Jiangsu, 210029, People’s Republic of China
,
Fei Quan2 The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, Jiangsu, 210021, People’s Republic of China
,
Zhongyu Lu2 The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, Jiangsu, 210021, People’s Republic of China
,
Jian Wang1 Medical Oncology Department, Jiangsu Province Hospital, Nanjing, Jiangsu, 210029, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-8992-8718
ORCID Icon &
Wen Gao1 Medical Oncology Department, Jiangsu Province Hospital, Nanjing, Jiangsu, 210029, People’s Republic of ChinaCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0002-0749-7676
ORCID Icon
Pages 535-540 | Received 29 Jan 2023, Accepted 13 Jun 2023, Published online: 07 Jul 2023

References

  • Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454. doi:10.1038/nature25183
  • Solomon BJ, Bauer TM, Mok TSK, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the Phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2023;11(4):354–366. doi:10.1016/S2213-2600(22)00437-4
  • Sankar K, Nagrath S, Ramnath N. Immunotherapy for ALK-rearranged non-small cell lung cancer: challenges inform promising approaches. Cancers. 2021;13(6):1476. doi:10.3390/cancers13061476
  • Li J, Zhang B, Zhang Y, et al. Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib. Transl Lung Cancer Res. 2021;10(3):1525–1535. doi:10.21037/tlcr-21-160
  • Solomon BJ, Kim D-W, Y-L W, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non–small-cell lung cancer. J Clin Oncol. 2018;36(22):2251–2258. doi:10.1200/JCO.2017.77.4794
  • Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–2177. doi:10.1056/NEJMoa1408440
  • Li W, Guo L, Liu Y, et al. Potential unreliability of uncommon ALK, ROS1, and RET genomic breakpoints in predicting the efficacy of targeted therapy in NSCLC. J Thorac Oncol. 2021;16(3):404–418. doi:10.1016/j.jtho.2020.10.156
  • Li W, Liu Y, Li W, Chen L, Ying J. Intergenic breakpoints Identified by DNA sequencing confound targetable kinase fusion detection in NSCLC. J Thorac Oncol. 2020;15(7):1223–1231. doi:10.1016/j.jtho.2020.02.023
  • Yun JW, Yang L, Park HY, et al. Dysregulation of cancer genes by recurrent intergenic fusions. Genome Biol. 2020;21(1):166. doi:10.1186/s13059-020-02076-2
  • Xiang C, Guo L, Zhao R, et al. Identification and validation of noncanonical RET fusions in non–small-cell lung cancer through DNA and RNA sequencing. J Mol Diagn. 2022;24(4):374–385. doi:10.1016/j.jmoldx.2021.12.004
  • Xu L, Wang X, Lu X, et al. Long-read sequencing identifies novel structural variations in colorectal cancer. PLoS Genet. 2023;19(2):e1010514. doi:10.1371/journal.pgen.1010514
  • Lee JK, Park S, Park H, Kim S, Kim YT. Tracing oncogene rearrangements in the mutational history of lung adenocarcinoma. Cell. 2019;177(7):1842–1857.e21. doi:10.1016/j.cell.2019.05.013
  • Nazaryan-Petersen L, Bjerregaard VA, Nielsen FC, Tommerup N, Tümer Z. Chromothripsis and DNA repair disorders. J Clin Med. 2020;9(3):613. doi:10.3390/jcm9030613
  • Liu S, Huang T, Liu M, et al. The genomic characteristics of ALK fusion positive tumors in Chinese NSCLC patients. Front Oncol. 2020;10:726. doi:10.3389/fonc.2020.00726
  • Young SJ, West SC. Coordinated roles of SLX4 and MutSβ in DNA repair and the maintenance of genome stability. Crit Rev Biochem. 2021;56(2):157–177. doi:10.1080/10409238.2021.1881433
  • Stoepker C, Hain K, Schuster B, et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet. 2011;43(2):138–141. doi:10.1038/ng.751
  • Kim Y, Lach FP, Desetty R, Hanenberg H, Auerbach AD, Smogorzewska A. Mutations of the SLX4 gene in Fanconi anemia. Nat Genet. 2011;43(2):142–146. doi:10.1038/ng.750
  • Cortés-Ciriano I, Lee JJ, Xi R, et al. Comprehensive analysis of chromothripsis in 2658 human cancers using whole-genome sequencing. Nat Genet. 2020;52(3):331–341. doi:10.1038/s41588-019-0576-7
  • Peng W, Li B, Li J, et al. Clinical and genomic features of Chinese lung cancer patients with germline mutations. Nat Commun. 2022;13(1):1268. doi:10.1038/s41467-022-28840-5
  • Cai C, Tang Y, Li Y, et al. Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients. Lung Cancer. 2021;152:104–108. doi:10.1016/j.lungcan.2020.12.018
  • Li Y, Duan P, Guan Y, et al. High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare ALK fusion sites: a case report. Transl Lung Cancer Res. 2022;11(1):100–110. doi:10.21037/tlcr-21-1039

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.